Results 41 to 50 of about 24,996 (206)

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia [PDF]

open access: yes, 2019
The majority of adult patients affected by B-cell acute lymphoblastic leukemia (B-ALL) will relapse after an initial response, while approximately 20% will display primary resistant disease. Patients suffering from relapsed/refractory B-ALL have a very
Lanza, Francesco   +2 more
core   +1 more source

Clinical and molecular characteristics of MEF2D fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in MEF2D-HNRNPH1 gene fusion

open access: yesHaematologica, 2019
Fusion genes involving MEF2D have recently been identified in precursor B-cell acute lymphoblastic leukemia, mutually exclusive of the common risk stratifying genetic abnormalities, although their true incidence and associated clinical characteristics ...
Kentaro Ohki   +38 more
doaj   +1 more source

Novel Markers in Pediatric Acute Lymphoid Leukemia: The Role of ADAM6 in B Cell Leukemia

open access: yesFrontiers in Cell and Developmental Biology, 2021
BackgroundThe extensive genetic heterogeneity found in the B cell precursor acute lymphoblastic leukemia (BCP-ALL) subtype of childhood ALL represents a potential repository of biomarkers. To explore this potential, we have carried out in silico analysis
Laila Alsuwaidi   +3 more
doaj   +1 more source

Outcome of T‐cell acute lymphoblastic leukemia/lymphoma: Focus on near‐ETP phenotype and differential impact of nelarabine

open access: yesAmerican journal of hematology/oncology, 2021
Early T‐cell precursor acute lymphoblastic leukemia/lymphoma (ETP‐ALL/LBL) is characterized by a distinct immunophenotype (CD1a‐negative, CD8‐negative, CD5‐negative or weak‐positive
Kiyomi Morita   +15 more
semanticscholar   +1 more source

Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies

open access: yesFrontiers in Immunology, 2021
T cells engineered with chimeric antigen receptor (CAR-T cells) are an effective treatment in patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma.
Marika Guercio   +20 more
doaj   +1 more source

VH replacement in rearranged immunoglobulin genes [PDF]

open access: yes, 2005
Examples suggesting that all or part of the V<sub>H</sub> segment of a rearranged V<sub>H</sub>DJ<sub>H</sub> may be replaced by all or part of another V<sub>H</sub> have been appearing since the 1980s ...
Brokaw JL   +21 more
core   +2 more sources

Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma

open access: yesBiomarker Research, 2019
B cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) frequently express CD19, CD20 and CD22 on the cell surfaces. Immunotherapeutic agents including antibodies and chimeric antigen receptor T cells are widely studied in clinical ...
Amandeep Aujla   +2 more
doaj   +1 more source

Aberrant positivity for CD79a in erythroid lineage cells – a finding observed in a subset of re-staging bone marrow trephine biopsies after treatment

open access: yesHaematologica, 2007
Aberrant expression of CD79a has been reported in neoplastic cells in peripheral T cell lymphoma, T-cell acute lymphoblastic leukemia and acute myeloid leukemia (especially those with t(8;21)).
Rashpal Singh Flora   +2 more
doaj   +1 more source

Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement

open access: yesHaematologica, 2022
Rarely, immunophenotypically immature B-cell precursor acute lymphoblastic leukemia (BCP-ALL) carries an immunoglobulin- MYC rearrangement (IG-MYC-r).
Simon Bomken   +39 more
doaj   +1 more source

Home - About - Disclaimer - Privacy